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Enterotoxigenic Escherichia coli (ETEC) infections are highly prevalent in developing countries, where clinical presentations
range from asymptomatic colonization to severe cholera-like illness. The molecular basis for these varied presentations,
which may involve strain-specific virulence features as well as host factors, has not been elucidated. We demonstrate
that, when challenged with ETEC strain H10407, originally isolated from a case of cholera-like illness, blood group A
human volunteers developed severe diarrhea more frequently than individuals from other blood groups. Interestingly,
a diverse population of ETEC strains, including H10407, secrete the EtpA adhesin molecule. As many bacterial adhesins
also agglutinate red blood cells, we combined the use of glycan arrays, biolayer inferometry, and noncanonical amino
acid labeling with hemagglutination studies to demonstrate that EtpA is a dominant ETEC blood group A–specific lectin/
hemagglutinin. Importantly, we have also shown that EtpA interacts specifically with glycans expressed on intestinal
epithelial cells from blood group A individuals and that EtpA-mediated bacterial-host interactions accelerate bacterial
adhesion and effective delivery of both the heat-labile and heat-stable toxins of ETEC. Collectively, these data provide
additional insight into the complex molecular basis of severe ETEC diarrheal illness that may inform rational design of
vaccines to protect those at highest risk.

Introduction

Enterotoxigenic Escherichia coli (ETEC) is a major cause of infectious diarrhea in the developing world (1, 2). These organisms are
estimated to be responsible for millions of infections and hundreds
of thousands of deaths, particularly of young children (3). Likewise, these pathogens are a principal cause of diarrhea in travelers
to endemic areas and an occasional cause of illness in developed
countries (4–7). Despite significant declines in deaths from acute
diarrhea (8), enteric infections caused by ETEC and other pathogens remain inextricably associated with malnutrition, stunted
growth, and impaired intellectual development (9), poorly understood sequelae that appear to result from gut dysfunction that follows repeated episodes of diarrhea in childhood (10). The ultimate
impact of these illnesses is further amplified by poor responses to
vaccines, increased mortality from other infections, and emerging
evidence that early gut dysfunction may be reflected in the subse-
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quent development of obesity and its attendant metabolic complications (11, 12). Consequently, these infections continue to exact
an extraordinary toll on global health.
The ETEC pathovar is defined by the production of plasmidencoded heat-labile (LT) and/or heat-stable (ST) enterotoxins
(13). Effective delivery of these toxins to cognate receptors on the
surface of intestinal epithelial cells is ultimately required to drive
net salt and water efflux into the lumen of the small intestine,
which results in diarrhea. Although ETEC was originally identified
in individuals suffering from severe cholera-like diarrhea (14), the
manifestations of infection may range from asymptomatic colonization to fulminant illness clinically indistinguishable from that
caused by Vibrio cholerae (15–17). The molecular basis for these
varied clinical presentations is presently unclear.
In the classic paradigm for ETEC virulence, these organisms
adhere to small intestinal epithelia via plasmid-encoded fimbrial
colonization factors to effect toxin delivery. However, recent studies suggest that the molecular pathogenesis of this diverse group
of pathogens may involve a repertoire of additional virulence features (18–20), including a variety of different adhesins to interact
with the intestinal epithelium (21).
Because of their impact on global health, these pathogens are
a principal target for vaccine development (22). Although there is
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Figure 1. Diarrheal severity is increased in blood group A–positive volunteers relative to those in the non-A blood groups. (A) Development of severe
diarrheal illness is accelerated in A blood group hosts. Kaplan-Meier curves indicate the proportion of subjects treated following the development of severe
diarrheal illness in volunteers belonging to A and non-A blood groups. Time-to-treatment data were available for 79 of the 106 subjects (18 subjects in the
A blood group and 61 subjects in the non-A group). Data were censored at 120 hours, when all remaining untreated individuals received antibiotics to clear
their infection. P = 0.015, log-rank (Mantel-Cox) testing. (B) Individuals of A blood group are more likely to develop MSD. Shown are relative risk data
from 4 independent controlled human infection model challenge studies of H10407 involving a total of 106 volunteers. Study numbers at left refer to
ClinicalTrials.gov designations. Box size indicates relative study size, and lines represent 95% CIs for the relative risk of severe diarrhea. The width of the
diamond indicates the 95% CIs for the pooled effect. The relative risk (pooled fixed effects) of MSD illness dichotomized by A (blood groups A and AB) vs.
non-A (O and B) was 1.441 (95% CI, 1.097 to 1.893; P = 0.009). Cochran’s Q test of heterogeneity was insignificant (P = 0.667, Q = 1.5682, df = 3).

currently no vaccine based on the classical virulence paradigm that
affords significant broad-based protection against ETEC (23), more
recently discovered virulence factors and an improved understanding of ETEC microbial pathogenesis could offer additional avenues
to protect those at highest risk for severe disease and uncover novel
molecular targets for future vaccine development (24).
Among the more recently described putative virulence molecules not targeted in the current generation of ETEC vaccines
is EtpA, a high–molecular weight secreted adhesin (25) bridge
between ETEC and intestinal epithelia (26). EtpA appears to be
conserved among a phylogenetically and geographically diverse
population of ETEC strains (27–29) and has shown promise as a
protective antigen in preclinical vaccine studies (30–33). Nevertheless, many questions remain to be answered about the contribution of this antigen and other molecules to disease pathogenesis and their potential use in vaccines relative to canonical ETEC
pathovar–specific adhesins.
One approach that has been used to explore ETEC pathogen
biology is the controlled human infection model, in which healthy
immunologically naive volunteers are challenged by ingestion of
enterotoxigenic E. coli. Notably, this model was used initially to
establish these toxin-producing E. coli as a cause of diarrheal illness in humans (34) and subsequently to examine virulence features of ETEC (35) and immune responses to experimental infection (36) and to conduct vaccine studies (37–40). The majority of
ETEC human-challenge studies conducted to date have involved
H10407, a prototype strain originally isolated from an adult with
severe, cholera-like illness in Bangladesh (41). While diarrheal ill-

ness following H10407 challenge tends to be significantly more
severe than that associated with other ETEC strains (42, 43), the
severity of diarrhea can vary substantially among volunteers within the same cohort, implicating the involvement of one or more
host factors in disease outcome.
Here, we demonstrate that, when challenged with H10407,
naive human volunteers with blood group A are at substantially
increased risk for severe diarrhea relative to other blood groups. In
addition, we found that the EtpA adhesin is a lectin that selectively
promotes interaction of ETEC with human small intestinal epithelial cells expressing blood group A glycans. These EtpA-dependent
ETEC-host interactions potentially provide a molecular basis for
selection and an accelerated course of illness in blood group A–
positive hosts.

Results

Blood group A volunteers challenged with ETEC have more severe disease. Because pathogen interactions with human blood group antigens can influence the outcome of infection by other gastrointestinal pathogens (44, 45), we questioned whether diarrheal severity
following ETEC infection was determined by blood group. To examine the impact of ABO blood groups on the development of diarrheal illness, we analyzed samples from 106 adult human volunteers
who had participated in any 1 of 4 earlier controlled human infection model studies in which they were challenged with ETEC strain
H10407 at the Johns Hopkins Center for Immunization Research
(Baltimore, Maryland, USA) and for whom prospectively collected
metadata on diarrheal severity were available. Each volunteer was
jci.org   Volume 128   Number 8   August 2018
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Table 1. Diarrheal illness and severity by blood group
Blood group
Diarrheal severity

O or B

A or AB

Total subjects (%)

None to mild
MSD
Total subjects

35 (44)
44 (56)
79

5 (19)
22 (81)A
27

40 (38)
66 (62)
106

Pearson χ2 = 5.694, 1 df, P = 0.017.

A

challenged with 1 to 2 × 107 colony-forming units of ETEC H10407
and was ETEC-naive prior to experimental challenge. All subjects
were treated with antibiotics upon meeting early treatment criteria
(Supplemental Table 1; supplemental material available online with
this article; https://doi.org/10.1172/JCI97659DS1) or at 120 hours
after inoculation to clear their infections.
Interestingly, we found that development of severe diarrheal
illness was significantly (P = 0.015) accelerated in individuals
with blood group A relative to those in non-A blood groups (Figure 1A), with volunteers in the A blood group requiring early initiation of antibiotic therapy more frequently (72%) than those in
blood group B or O (43%). Despite earlier antibiotic administration, maximal diarrheal volumes over 24 hours, total diarrheal volume prior to treatment, and the frequency of diarrheal episodes
tended to be higher in A versus non-A individuals (Supplemental
Figure 1, A–D). Notably, individuals with blood groups B or O were
considerably more likely to remain free of diarrhea or have mild
diarrhea (44%) following challenge than volunteers expressing
the A blood group (19%) (Table 1). Conversely, of the 106 subjects,
81% of those expressing the A blood group antigen (type A or AB)
had moderate-to-severe diarrhea (MSD) compared with 56% of
individuals with non-A (B or O) blood types (P = 0.017), and the
overall relative risk of MSD among individuals with the A blood
group compared with the non-A blood groups was 1.44 (95% CI
= 1.1–1.9, P = 0.009) (Figure 1B and Supplemental Table 2). These
data therefore suggest that, upon challenge with H10407, blood
group A volunteers (Supplemental Tables 3 and 4) are markedly
more likely to manifest the severe, cholera-like spectrum of illness
originally associated with this isolate.
EtpA interacts specifically with blood group A glycans. Pathogens use adhesins possessing glycan-specific lectin activity (46)
to engage blood group antigens expressed on mucosal surfaces,
including the gastrointestinal tract (47). The apical surface of
intestinal epithelial cells is heavily decorated with a variety of
glycoproteins that form the glycocalyx (48), and glycosylation patterns of these proteins are in part determined by blood group (47,
49). Because earlier studies had suggested that EtpA, a secreted
adhesin molecule discovered in H10407 (25), engages the surface
of gastrointestinal epithelia, we conducted glycan-array screening
to further elucidate the nature of EtpA-mediated bacterial adhesion. Using recombinant EtpA (rEtpA) to probe arrays containing more than 400 unique glycan species, we found that rEtpA
interacted almost exclusively with glycans related to blood group
A. In contrast, we observed little or no binding to other glycans,
including those of blood group B or blood group O (Figure 2A and
Supplemental Data Set 1). Next, in biolayer interferometry experi3300
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ments, we found that EtpA interacted with blood group A–related
glycans with high affinity when the glycan was presented as a
multivalent trisaccharide conjugated to polyacrylamide (PAA):
GalNAcα1-3 (Fucα1,2)Galβ-PAA, where Gal indicates galactose;
kD, ~9 × 10–8 M (Figure 2B). Similarly, we demonstrated that EtpA
can engage N-acetylgalactosamine (GalNAc) (kD, ~1.6 × 10–8 M),
the terminal sugar in blood group A, with higher affinity than Gal
(kD, ~1.9 × 10 –7), the terminal sugar of blood group B (Figure 2C).
Collectively, these studies suggest that the EtpA adhesin is a blood
group A–specific lectin.
Many bacterial adhesins possess the ability to agglutinate
RBCs. Included among these adhesins is filamentous hemagglutinin from Bordetella pertussis (50), a component of acellular
pertussis vaccines (51), which, like EtpA, belongs to the 2-partner
family of bacterial exoproteins (25). We found that EtpA could
decorate the surface of human RBCs belonging to blood group
A1 (Figure 3A) and, to a lesser extent, cells from those individuals
from blood group A2 who exhibit lower levels of the glycosyltransferase enzyme activity required for addition of terminal GalNAc
residues that determine the A blood group (52); however, only a
small percentage of blood group B or O erythrocytes had detectable EtpA on the surface. Similarly, in RBC pull-down assays, more
rEtpA remained associated with erythrocytes from the A1 and A2
blood groups (Figure 3B) than those from the B or O blood groups.
In addition, incubation of EtpA with RBCs from blood group A1
resulted in agglutination, but yielded poor agglutination activity
with other RBCs (Figure 3C). In addition, pretreatment of target
A1 cells with α-N-acetylgalactosaminidase completely abrogated
the hemagglutinin activity of EtpA (Figure 3D) as did addition of
excess GalNAc, but not GlcNAc or Gal, the terminal sugar of blood
group B (Supplemental Figure 2). We also demonstrated that latex
microparticles coated with EtpA specifically agglutinated A1 RBCs
(Figure 3E). EtpA therefore belongs to a large family of bacterial
adhesins that possess lectin/hemagglutinin activity (46), and this
protein preferentially targets GalNac residues presented in the
context of the A blood group.
EtpA is a predominant blood group A–binding partner in ETEC.
Next, to determine whether EtpA is the predominant blood group
A–binding partner in ETEC, we examined interaction of A blood
group glycans with subcellular protein fractions isolated from
H10407. Blood group A glycans interacted only with a high molecular weight species (in excess of 150 kD) in culture supernatants,
with no detectable interaction with preparations from the inner or
outer membranes (Figure 4A). Because the EtpA adhesin is the only
known ETEC-specific virulence molecule in the ETEC secretome
of this size (53), we next compared binding of blood group A glycans to secreted proteins from the WT H10407 strain and isogenic
etpA mutants. Binding occurred only in supernatants prepared from
WT ETEC or the complemented etpA mutant strain, but not the
etpA isogenic deletion mutant (Figure 4, B–D). Interestingly, blood
group A erythrocytes have been traditionally used to screen for the
presence of CFA/I fimbriae in ETEC (54). However, we found that
CFA/I mediated nonspecific hemagglutination of RBCs regardless
of blood type, a result that is consistent with the idea that CFA/I
interactions are mediated via sialic acid (55) (Supplemental Figure
3). To further confirm the role of EtpA in mediating interaction with
the A blood group, we next tagged the ETEC proteome using the
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Figure 2. EtpA interacts preferentially with blood group A glycans. (A) Glycan-array data (top row) demonstrating EtpA binding predominately to blood
group A glycans. The top 100 of 411 glycans are ranked in order of diminishing binding activity from left to right. BSA (middle row) is shown as a control.
Values represent background-corrected median data from 2 experimental replicates. Distribution of blood group (bg) binding is shown in the bottom row
of the figure. Heatmap key (lower right) shows relative fluorescence units (rfu) and coding for blood group antigens. Names for glycans correspond to
Supplemental Data Set 1. (B) EtpA binding to blood group A glycans assessed by Bio-Layer Interferometery (Pall ForteBio Corp.) assays. Data are representative of 3 independent experiments. Blood group A3 refers to the biotinylated trisaccharide-PAA conjugate GalNAcα1-3 (Fucα1,2)Galβ-PAA-biotin; blood
group A2 refers to the disaccharide conjugate GalNAcα1-3Galβ-PAA-biotin. (C) EtpA binding to terminal GalNAc residues relative to Gal schematic (right)
shows structures of blood groups A and B terminating in GalNAc and Gal sugars, respectively. Blood group O (core H) lacks either terminal sugar residue.

noncanonical amino acid azidonorleucine (ANL) (56) and incubated tagged supernatant and outer membrane protein (OMP) fractions with erythrocytes. Again, we found that a single band from
tagged WT supernatant, corresponding to EtpA, bound appreciably only to A1 erythrocytes (Figure 4E). However, testing of ANLlabeled OMPs purified from H10407 failed to detect any specific
interactions of ETEC OMPs with RBCs of any major blood group
(Supplemental Figure 4), further suggesting that the secreted EtpA
molecule is the dominant blood group A–specific lectin expressed
on the surface of ETEC. We also demonstrated that EtpA expression
by a geographically diverse group of ETEC conferred the ability to
bind blood group A, suggesting that these findings are not limited to
the H10407 prototype strain (Supplemental Figure 5, A–D).
EtpA directs ETEC interaction with blood group A on host intestinal epithelial cells. We questioned whether blood group A–related

glycans on the surface of intestinal enterocytes might therefore
direct EtpA-mediated interactions required for effective bacterial adhesion and toxin delivery. Using HT-29 intestinal cells
derived from a blood group A–positive host, we found that EtpA
bound to the surface of these cells and colocalized with blood
group A glycans (Figure 5A). Conversely, rEtpA bound very poorly
to the surface of HT-29A–/– cells, an HT-29–derived line that was
CRISPR-Cas9 engineered to eliminate the gene encoding the glycosyltransferase responsible for the addition of terminal GalNac
residues to the core H (blood group O) antigen (45). Likewise,
we found that EtpA from ANL-tagged WT ETEC interacted preferentially with HT-29 parental cells compared with the mutant
HT-29A–/– cells (Figure 5B). Interestingly, EtpA-expressing ETEC
localized to regions of blood group A expression on the surface
of HT-29 cells (Figure 5C), and EtpA-expressing ETEC adhered
jci.org   Volume 128   Number 8   August 2018

3301

RESEARCH ARTICLE

The Journal of Clinical Investigation  
Figure 3. EtpA is a blood group A–specific hemagglutinin.
(A) Binding of rEtpA to the surface of group A1 and A2 RBC
ghosts relative to B and O RBCs is shown in FACS data and
a graph. (B) RBC pull-down of rEtpA with different blood
group ghost erythrocytes. Shown in the immunoblot is
rEtpA-myc-his identified by anti-myc antibodies. (C) EtpA
agglutinates A1 RBCs, but exhibits minimal or no hemagglutination activity with RBCs from those with A2, B, or O
blood groups. The column on the right includes anti–A blood
group antibodies as a positive control. (D) EtpA-mediated
hemagglutination is dependent on terminal GalNac residues.
A1 RBCS pretreated with α-N-acetylgalactosaminidase (top
row) fail to agglutinate in the presence of rEtpA. Shown (row
2, left) are positive controls (no enzyme pretreatment) and
blood group O–negative controls (bottom rows). (E) EtpAcoated latex microspheres (top row) agglutinate RBCs from
blood group A, but not B or O. Bottom row shows BSA-coated
particles as controls. Each of the images are representative
of 3 experimental replicates. Original magnification, ×40.

more readily to parental cells expressing blood group A (Figure
5, D and E, and Supplemental Figure 6A). Importantly, we found
that optimal delivery of LT toxin required both EtpA (Supplemental Figure 6B) and the presence of the A blood group antigen
(Figure 5F). Similarly, we noted that addition of exogenous GalNAc impaired both EtpA-mediated adhesion and toxin delivery to
HT29 parental cells (Supplemental Figure 7, A and B), suggesting
that this terminal glycan on blood group A is important for EtpA
pathogen–epithelial cell interactions. Notably, while purified LT
was significantly less potent than cholera toxin (CT) in activating
cAMP in target cells, direct toxin-mediated activation of this cyclic
nucleotide was actually enhanced in cells lacking the A blood
group (Supplemental Figure 8), recapitulating recent observations
with CT (45). Collectively, these data suggest that the presence of
blood group A effectively promotes bacterial adhesion and ETEChost interactions that culminate in enhanced toxin delivery.
HT-29 cells are derived from a metastatic colorectal carcinoma, and glycan distribution can vary significantly with location
within the gastrointestinal tract (57). In addition, ETEC are thought
to preferentially target the small intestine, where the bulk of fluid
secretion occurs following colonization, rather than the colon.
We sought, therefore, to confirm these interactions using
small intestinal enteroids (58, 59) derived from human stem
cells obtained from individuals belonging to each of the major
ABO blood groups. Using ileal enteroids, we found that, while
EtpA clearly bound to cells from group A individuals, the purified
3302
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adhesin bound very poorly to cells expressing either B or O blood
groups (Figure 6, A and B). We also found EtpA-expressing bacteria within areas of blood group A expression on the epithelial surface of polarized enteroids (Figure 6C), and interestingly, we also
observed apparent rearrangement or “footprints” of the A blood
group at sites of bacterial attachment, suggesting an intimate
interaction of ETEC with these cell-surface glycans (Figure 6D).
Finally, we found that ETEC adhered much more readily to polarized intestinal monolayers derived from individuals with blood
group A compared with other blood groups (Figure 6E) and that
adhesion of WT ETEC to A blood group enteroids was significantly accelerated relative to that of bacteria lacking etpA (Figure 6F),
culminating in enhanced toxin delivery by the EtpA-expressing
WT (Figure 6, G and H). EtpA therefore appears to be a dominant
pathovar-specific lectin uniquely capable of preferentially engaging A blood group glycans expressed on small intestinal epithelial
surfaces to accelerate effective ETEC pathogen-host interactions.

Discussion

Blood group–dependent microbial-host interactions can dictate
clinical outcomes of infection with important gastrointestinal
pathogens. In the case of Helicobacter pylori, the BabA adhesin
facilitates attachment to the gastric mucosae by engaging ABO
(60) and Leb, blood group antigens potentiating the delivery of
other secreted virulence factors that lead to development of gastric
ulcers and cancer (44, 60, 61). Similarly, the clear epidemiologic
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Figure 4. EtpA is a dominant blood group A–binding partner of ETEC
H10407. (A) Blood group A antigen far-Western blot with subcellular
fractions of ETEC H10407 including supernatant (S), outer membrane
(OM), and inner membrane (IM) demonstrates binding of biotinylated
blood group A to high molecular weight protein in concentrated culture supernatant. (B) Coomassie-stained gel of supernatant proteins
from H10407 (WT), etpA mutant jf1668, etpA mutant complemented
with the etpBAC locus plasmid pJY019 (etpA(P+); etpA(P–)) equals
mutant complemented with cloning vector alone. (C) EtpA immunoblot confirming the presence of EtpA in culture supernatants from
H10407 and the complemented mutant. (D) Far-Western blot of
culture supernatants shown in B and C shows binding of biotinylated
blood group A only in the presence of EtpA. (E) EtpA is the dominant
A blood group–specific interacting partner among ETEC proteins from
ANL-labeled bacteria. Shown is a fluorescence image of ANL-labeled
proteins from ETEC H10407 that interact with erythrocyte ghosts
from A1, A2, B, and O blood groups (middle, RBCs/ANL). RBC ghosts
alone are shown at left, and input protein (ANL) from H10407 and the
etpA deletion mutant (jf1668) are shown at right. The migration of
EtpA is indicated by the arrow, and TAMRA-labeled rEtpA is shown
at far right as a positive control. Each image is representative of 3
experimental replicates.

associations between severe V. cholerae infections and the O blood
group (62–66) are reflected in recent observations that CT preferentially activates enterocytes of blood group O lineage (45). Both
CT and the closely related LT toxin of enterotoxigenic E. coli appear
to share in a differential binding of blood group antigens that favors
intoxication of blood group O enterocytes (67, 68). Interestingly,
because of the molecular similarity between CT and LT, some earlier field studies examined ETEC outcomes relative to blood group
with the implicit assumption that LT-producing ETEC would lead
to more severe disease following infection of O blood group hosts;
however, these studies yielded conflicting results (69, 70).
In contrast, from the human volunteer ETEC challenge studies, a surprising, but clear, relationship between the A blood group
and disease severity began to emerge. The ETEC controlled
human infection model has a number of potential advantages
over prior field studies (3, 62, 69, 70) in defining a molecular basis
for disease. First, the present studies were confined to ETECnaive adults challenged with a defined inoculum of a single strain
(H10407) isolated from an individual with severe cholera-like illness (41). The controlled human infection model may have therefore permitted us to unmask somewhat subtle molecular associations that might have otherwise been hidden by confounding
variables common to field studies of enteric infections in developing countries, including malnutrition, breast feeding, altered
microbiota, and coinfection with other enteric pathogens as well
as the genetic variability inherent in the infecting ETEC strains.

The studies presented here provide an expanded view of ETEC
pathogen-host interactions beyond a classical paradigm in which
these organisms engage the intestinal surface via fimbrial colonization factors and deliver LT and/or ST enterotoxins. The present
studies of ETEC paint a more complex picture in which A blood
group expression potentially facilitates EtpA-mediated lectinspecific bacterial interactions with intestinal epithelia that culminate in effective toxin delivery and symptomatic diarrheal illness.
Our studies suggest that the many ETEC strains that produce
the EtpA adhesin (27, 29) may be particularly well equipped to
preferentially infect hosts who express the A blood group antigen
on mucosal surfaces. When infected with H10407, an EtpA-producing strain, immunologically naive subjects with blood group
A appear to be at significantly increased risk for diarrheal illness,
and the ensuing diarrhea tends to be more severe relative to the
other major blood groups. Intriguingly, the ETEC H10407 strain,
isolated from a case of severe cholera-like diarrheal illness more
than 40 years ago, is typically among the most virulent strains to
be tested in human-challenge studies (43, 71).
It is likely however, that while EtpA leads to enhanced virulence in blood group A hosts, other putative virulence factors identified in H10407, including the mucin-degrading EatA protease
(19), collectively augment virulence by accelerating toxin delivery
that culminates in severe diarrhea.
Several additional features of our studies deserve comment.
We were not able to examine “secretor status,” i.e., expression
jci.org   Volume 128   Number 8   August 2018
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Figure 5. A blood group–dependent interactions of EtpA and ETEC with
intestinal epithelia. (A) EtpA binds to regions of blood group A expression
on the surface of HT-29 epithelial cells. Shown in columns from left to right
are blood group A (green, antibodies against blood group A and fluorescent conjugate αbgA/AF488); nuclei (blue, DAPI); biotinylated EtpA (red,
SA-coated Qdots594); and merged images. Middle row: no EtpA control.
Bottom row: no EtpA binding to the surface of HT29A–/– cells engineered
to remove the α1→3 GalNac glycosyltransferase required for A antigen
expression. Original magnification, ×100. (B) EtpA preferentially engages
cells expressing A blood group. Key: upper left indicates the target (bait)
cell lines used to attract ANL-labeled bacterial (prey) proteins from H10407
(WT) or the etpA mutant. Labeled rEtpA and the arrow at left are shown
to indicate the predicted migration of EtpA. Lanes at far right show input
proteins from the EtpA-expressing H10407 WT and the etpA mutant. (C)
Localization of EtpA-expressing ETEC to areas of blood group A expression on the surface of HT-29 cells. Original magnification, ×63. Images in
A–C represent 1 of 3 experimental replicates. (D) EtpA and blood group A
are required for optimal adhesion. Data are representative of 4 independent experiments. HT-29A–/– data include results from 2 independently
generated engineered blood group A glycosyl transferase mutant lines
(1e6, circular symbols; and 1g10, square symbols; n = 8 technical replicates
in total). *P = 0.03, ANOVA, Kruskal-Wallis. (E) Blood group A accelerates
adhesion of ETEC to target intestinal epithelial cells (n = 8 technical replicates for HT-29 cells and n = 6 technical replicates for HT-29–/– cells; representative of 2 independent experiments); symbols represent mean ± SEM.
**P = 0.003; ***P = 0.0003, Mann-Whitney U test, 2-tailed comparison.
(F) Presence of A blood group and EtpA are required for optimal delivery
of heat-labile toxin by ETEC (n = 5 technical replicates representative of 3
independent experiments). **P < 0.01, ANOVA, Kruskal-Wallis.

of the FUT2 α1,2 fucosyltransferase required to synthesize ABO
blood group antigens on intestinal epithelia (52). Because approximately 20% of the population are nonsecretors due to defects
in FUT2 (72), it is likely that some of the A blood group–positive
individuals did not express the A antigen on their gastrointestinal
epithelia. Theoretically, this might account for some individuals
in the A blood group who failed to become ill following challenge.
Conversely, while the A blood group is a risk factor in this model,
the development of severe diarrheal illness among non-A volunteers demonstrates that expression of A glycans is not an absolute
requirement for disease. V. cholerae infections provide an important analogous paradigm for severity of illness related to blood
group. While severe cholera is significantly associated with the O
blood group, it is not exclusively observed in blood group O individuals (66). We should also note that the ETEC-challenge studies were done with a relatively high inoculum of bacteria (~107)
designed to assure a reasonable attack rate (73), a feature that may
not be reflected in naturally occurring infections in young children
where the A blood group also appears to be a risk for development
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of symptomatic infections (3). It is also worth noting that volunteers in these studies were treated with antibiotics to clear the
infection once they met the definition of severe diarrheal illness, a
feature that might also have affected the ultimate outcome.
The secreted EtpA lectin likely acts in concert (21) with at least
2 additional glycan-binding tip adhesins of ETEC fimbriae with
different substrate specificities. These include FimH of the chromosomally encoded type 1 pili, which binds to mannosylated surface proteins on epithelial cells (74), and the CfaE adhesin located
at the tips of canonical plasmid-encoded CFA/I pili, which putatively binds to sialylated glycoproteins (55, 75). The latter is consistent with the observation that ETEC expressing CFA/I mediates mannose-resistant (54) and neuraminidase-sensitive (75, 76)
hemagglutination in all major blood groups and across species to
include chicken and bovine erythrocytes. Therefore, it appears
that EtpA is the only blood group A–specific lectin identified in
ETEC to date. Nevertheless, we cannot rule out the possibility that
our studies failed to identify another blood group A lectin that was
not efficiently expressed under laboratory culture conditions.

RESEARCH ARTICLE

The Journal of Clinical Investigation  

Figure 6. EtpA and EtpA-expressing ETEC interact preferentially with the surface of blood group A enteroids. (A) Confocal imaging of EtpA binding to
surface of polarized small intestinal enteroid monolayers from a blood group A subject. Differential interference contrast (DIC) image at bottom shows
architecture of polarized enteroids on Transwell filter. Original magnification, ×63. (B) Kinetic ELISA quantification of biotinylated EtpA binding to surface
of small intestinal enteroid cells from blood groups A, B, and O (n = 4 technical replicates representative of 3 separate experiments). *P < 0.05; **P < 0.01,
ANOVA, Kruskal-Wallis. (C) Association of EtpA-expressing ETEC H10407 with A blood group on surface of small intestinal cells. Images represent volocityprocessed confocal laser-scanning microscopy (CLSM) data of ETEC H10407 (red) to blood group A (green) and nuclei (blue). Lower panel shows polarized
orientation of cells with bacteria adherent to the apical surfaces of enterocytes. Original magnification, ×63. (D) Top panel: CLSM of ETEC (green) and
A blood group (red) on jejunal enteroids. Bottom panel: A blood group “footprints” (arrows) at sites of bacterial attachment. Data shown in C and D are
representative of 3 experimental replicates. Original magnification, ×60. (E) Bacterial density on surface of small intestinal enteroids determined by CLSM
quantification of H10407 (serotype O78). Quantitation based on imaging 10 fields per blood group, at ×20 magnification. *P = 0.039; #P < 0.0001, ANOVA,
Kruskal-Wallis. (F) Adhesion of WT H10407 and etpA mutant bacteria to blood group A small intestinal enteroids (n = 5 technical replicates; representative of 3 biological replicates). Bars represent geometric mean values. (G) Production of cAMP by blood group A target enteroids following infection by WT
(H10407) or the etpA mutant. Data represent total of 5 technical replicates from 2 separate experiments. (H) Production of cGMP by blood group A small
intestinal enteroids following infection with WT (n = 6) or the etpA mutant (n = 4). Data are representative of 3 independent biological replicates. Inset
graph indicates relative (mean ± SD, n = 6 technical replicates) production of heat stable toxin (ST) by the WT (blue bars) vs. the mutant (gray bars).
**P < 0.01, Mann-Whitney U test, 2 tailed nonparametric testing.

Interestingly, findings presented here are in keeping with
earlier birth-cohort studies of children under the age of 2 years in
Bangladesh who also demonstrated an association between the
A blood group and symptomatic ETEC infection (3). Therefore,
while our recent studies have potentially important clinical and
vaccinology implications, further study of the relationship among
blood group, disease severity, and antigen expression could guide
and inform use of these antigens in vaccines.
These additional molecular details regarding the nature of
ETEC pathogen–host interactions could promote an improved
understanding of the virulence elements and host determinants
related to the most severe forms of illness that are clinically indistinguishable from severe cholera (15–17). Consequently, identifi-

cation of EtpA as blood group A lectin could focus antigen development and inform vaccine design to specifically protect individuals
that are at highest risk for severe cholera-like diarrheal illness.

Methods

ETEC controlled human infection volunteer challenge studies. Samples for
blood group analysis were obtained from a convenience sample of 106
human volunteers from 4 prior independent controlled human infection model ETEC challenge studies conducted at the Johns Hopkins
Center for Immunization Research (ClinicalTrials.gov NCT01739231,
NCT01060748, NCT00844493, and NCT01922856). All volunteers
were experimentally infected with 1 to 2 × 107 colony-forming units
of the EtpA-expressing ETEC strain H10407. Subjects in these studies
jci.org   Volume 128   Number 8   August 2018
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were treated with antibiotics once they met previously defined endpoint criteria (summarized in Supplemental Table 1) or at 120 hours
after inoculation to clear their infections. Additional details of the of
the study design are included in the Supplemental Methods.
Glycan-array screening. Glycan arrays containing 411 separate features were fabricated as previously reported, except for the addition
of a washable fluorescent dye, the free acid of DyLight 649 (0.7 μg/
ml, Thermo Scientific), to the print buffer as an indicator of successful liquid deposition and spot morphology. The array format and assay
have been described previously (77) along with analysis of reproducibility (78) and validation with numerous antibodies and lectins (79,
80). Slides were blocked overnight at 4°C with 3% BSA (w/v; 200 μl/
well) in PBS and then washed 6 times with PBST (PBS with 0.05%
Tween 20; 200 μl/well). Polyhistidine-tagged rEtpA-6His was diluted
to final concentrations of 20 and 200 μg/ml in PBST buffer containing
3% BSA (MilliporeSigma) and 1% HSA (MilliporeSigma), and then 50
μl of each sample was added into 2 different wells on different slides.
Incubation buffer alone served as the negative control for samples
analyzed in duplicate. After incubation with rEtpA for 2 hours at 37°C
in an orbital shaker (100 rpm), arrays were washed and then probed
with mouse monoclonal IgG anti-His5 antibody (QIAGEN, 34660)
diluted 1:500 to a final concentration of 0.4 μg/ml (1 hour at 37°C; 100
rpm), followed by DyLight 549–conjugated affinity purified goat antimouse IgG (Jackson ImmunoResearch, 115-505-071; 1 hour at 37°C;
100 rpm). After washing 7 times with PBST (200 μl/well), slides were
immersed in wash buffer for 5 minutes and centrifuged at 200 g for
5 minutes. Slides were scanned at 10 μm resolution with a GenePix
4000B Microarray Scanner (Molecular Devices Corp.) with excitation/emission wavelengths of 532/575 nm and analyzed with GenePix
Pro 6.0 software, as previously reported (77). Heatmaps were assembled in R version 3.2.2 (The R Foundation for Statistical Computing),
using the gplots and RColorBrewer packages made available through
the Comprehensive R Archive Network (CRAN; http://cran.wustl.
edu/). Additional details of the glycan-array screening can be found
in Supplemental Methods.
Bacterial strains and culture conditions. ETEC strain H10407 was
provided from GMP stock produced at the Walter Reed Army Institute
of Research (Silver Spring, Maryland, USA). The etpA mutant H10407
(jf1668) and complemented (jf1697) strains were generated in previous
studies. ETEC strains were routinely grown in Luria broth (LB) or LB
agar (2% agar) at 37°C from glycerol stocks preserved at –80°C. Bacterial strains and plasmids used in this study are listed in Supplemental
Table 5. Strains 100137, 200145, 30051, 400643, 500632, 601142, and
700241 were provided by David Rasko (Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland,
USA). Strain 12005000131-1 was provided by Elizabeth Cebelinski
(Molecular Epidemiology Section of the Infectious Diseases Laboratory, Minnesota Department of Health, St. Paul, Minnesota, USA).
Protein expression and purification. The 2-partner secreted EtpA
glycoprotein was purified from culture supernatants of E. coli Top10
coexpressing plasmids pJL017 and pJL030 (81). Briefly, E. coli Top10
carrying pJL017 and pJL030 (Supplemental Table 5) was grown in LB
with ampicillin (100 μg/ml) and chloramphenicol (15 μg/ml) at 37°C,
in a shaking incubator at 230 rpm, until OD 600 nm reached approximately 0.5–0.6. Recombinant protein expression was then induced
with 0.0002% arabinose for 6 hours at 37°C. Culture supernatant was
concentrated using a 100 kD Molecular Weight Cutoff (MWCO) filter
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(Millipore), and rEtpA-myc-6His protein was purified using immobilized metal affinity chromatography as described previously (81).
ETEC subcellular fractionation and far-Western analysis. ETEC
H10407 was grown overnight in 10 ml cultures of LB at 37°C as
described above, diluted into 500 ml cultures the next morning, and
grown for 3 hours at 37°C. Cells were harvested by centrifugation at
5000 g for 10 minutes at 4°C and the pellet resuspended in 8 ml 50 mM
Tris buffer pH 7.8 containing 1 mM EDTA and 1 mg DNAse. Subcellular fractions were then prepared as previously described (82). Briefly,
cells were disrupted using a French press, followed by the addition of
2 mM MgCl2 to E. coli lysate and centrifugation at 5000 g for 10 minutes at 4°C to remove large debris/intact cells. Supernatant was collected, supplemented with PMSF to a final concentration of 1 mM, and
ultracentrifuged at 100,000 g for 1 hour at 4°C. Supernatant from this
step was saved as a cytosolic fraction. The remaining cell pellet was
resuspended in ice-cold 10 mM HEPES pH 7.4, layered over a gradient of 69%, 52.8%, and 26.4% sucrose in HEPES pH 7.4 and ultracentrifuged at 113,000 g for 16 hours at 4°C. The visible upper layer containing inner membranes and the lower high-density layer with outer
membranes were collected. Membrane proteins were reconstituted in
ice-cold HEPES pH 7.4 and centrifuged for 1 hour at 100,000 g, 4°C.
Finally, the protein pellets from the inner and outer membranes were
resuspended in 0.25 and 0.5 ml dH2O, respectively.
Far-Western blotting was used to test blood group A glycan interaction with ETEC proteins. Briefly, approximately 10 μg of ETEC proteins were resolved by SDS-PAGE on NuPAGE 4%–20% Tris-Glycine
Gel (Life Technologies) and transferred to nitrocellulose membranes.
Membranes were blocked with 5% BSA in TBS-T (Tris[hydroxymethyl]
aminomethane–buffered saline, 0.01% Tween-20) for 1 hour and then
incubated with a final concentration of 5 μg/ml of biotinylated multivalent blood group A trisaccharide (Glycotech; 01-032) overnight at
4°C. Biotinylated glycans were detected using streptavidin-HRP (SAHRP) conjugate (1:20,000), and EtpA was detected by immunoblotting using anti-EtpA rabbit polyclonal antibody.
Hemagglutination studies. We examined the ability of EtpA to
agglutinate human erythrocytes belonging to blood groups A1, A2, B,
and O (Immucor, catalog 0002338). Briefly, 2-fold dilutions of rEtpA
in PBS in a final volume of 10 μl were mixed with 40 μl of approximately 1% cell suspensions (in PBS) of RBCs expressing the A1, A2, B,
and O antigens in 96-well round-bottom plates, then incubated for 30
minutes at 4°C. Plates were then imaged to show agglutinated versus
nonagglutinated (settled) RBCs. In parallel experiments, recombinant
polyhistidine-tagged EtpA was immobilized onto cobalt-impregnated
super-paramagnetic polystyrene beads (Dynabeads TALON, Thermo
Fisher, catalog 101.01D) that were then incubated with RBCs.
To examine the specificity of EtpA-induced agglutination of RBCs
expressing the A antigen, agglutination assays were performed in the
presence of excess terminal sugars specific to individual blood types:
GalNAc (blood group A), Gal (blood group B), or control GlcNAc at 50
mM final concentration. α-N-acetylgalactosaminidase (P0734S; New
England Biolabs) was used to remove terminal GalNAc from the A
blood group antigen by incubating 50 μl of a 1% RBC suspension with
20 U α-N-acetylgalactosaminidase for 4 hours at 37°C.
To examine the potential contribution of the CFA/I colonization
factor to hemagglutination, we followed a protocol similar to that
previously described by Evans (54). Briefly, bacteria were grown overnight on CYE agar (1% casamino acids; BD), 0.15% yeast extract (BD),
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2% agar, 0.005% MgSO4, and 0.0005% MnCl2. Bacteria were resuspended in PBS (A600 3.0) and diluted 4-fold prior to use. Human erythrocytes (Immucor, 2%–4% suspension) were diluted 1:4 in PBS, and 25
μl each of bacterial and RBC suspension were added to a flat-bottomed
96-well plate and rotated at 1,000 g at RT for 15 minutes, after which
agglutination was visualized. Control anti–A IgM antibodies (Immucor) were used at 1:32 dilution.
FACS. RBC ghosts were prepared at 4°C. 800 μl of a 2%–4% suspension of RBCs was washed once in PBS, resuspended in 1.5 ml of
ghost buffer (50 mM NaPO4, pH 8.0), and incubated on ice for 1 minute. RBCs were pelleted at 25,000 g for 10 minutes, then washed twice
in ghost buffer. Ghosts were resuspended in 400 μl PBS.
For FACS analysis, 15 μg biotinylated EtpA or BSA was added
to 190 μl of RBC ghosts and rotated at RT for 1.5 hours. Cells were
washed twice in PBS and pelleted by spinning at 25,000 g for 5 minutes, rotated for 30 minutes with a 1:200 dilution of SA-conjugate
nanocrystals (Qdot 525, Q10141MP, Thermo Fisher), and then
washed twice in PBS and resuspended in 200 μl of PBS. Fluorescence
was measured using FACSCalibur (BD Biosciences), and data were
analyzed using FlowJo software, v10.
Molecular cloning of mutant Met-RS. To permit noncanonical
amino acid labeling of ETEC proteins with azidonorlucine (Anl), a
mutant form of the methionyl-tRNA synthetase (NLL-MetRS) gene
from pAM1 (56) was cloned (In-Fusion, Clontech) into the NcoI and
EcoRI sites of pBAD/Myc-His B (Supplemental Table 5) using primers
jf091715.1 and jf091715.2 (Supplemental Table 6). The resulting plasmid pBAD-MetRS was transformed into WT H10407 or the jf1668
etpA mutant to generate jf3422 and jf3904, respectively.
Protein interaction studies using noncanonical amino acid labeling
of ETEC. Proteomes of strains jf3422 and jf3904 bearing the MetRS
expression plasmid were labeled by growth with azidonorleucine as
previously described. Briefly, strains were grown overnight in LB containing 100 μg/ml ampicillin, 0.2% arabinose, and 1 mM azidonorleucine (HAA1625, Iris Biotech GmbH). Cell-free supernatants were
concentrated 10-fold using 10 kD MWCO centrifugal concentrators
and dialyzed against PBS prior to use.
OMPs were prepared from ANL-tagged bacteria grown in the
same fashion using an established protocol (83). Briefly, labeled bacteria were resuspended in 20 ml ice-cold lysis buffer (50 mM Tris, 1 mM
EDTA, pH 7.8) and lysed by sonication (4 × 20-second bursts). Approximately 1 mg of DNase I (MilliporeSigma) was added to each tube
and the extracts adjusted to 2 mM MgCl2 and 100 μM PMSF. Intact
cells and large debris were removed by low-speed centrifugation at
3,000 g for 10 minutes, and membranes were pelleted from clarified
lysates by ultracentrifugation for 1 hour at 100,000 g. Membrane pellets were then resuspended in 2 ml 10 mM HEPES pH 7.4 and layered
onto discontinuous sucrose gradients consisting of a top layer of 0.77
M sucrose, a middle layer of 1.44 M sucrose, and a bottom layer of 2.02
M sucrose. After centrifugation at 113,000 g for 16 hours at 4°C, the
OMPs were recovered from the interface between the 1.44 and 2.02
M layers. OMP pellets were washed by resuspension in 14 ml 10 mM
HEPES pH 7.4, collected by centrifugation at 100,000 g for 1 hour, and
resuspended in 0.5 ml PBS.
Erythrocyte membranes were prepared using the method previously described by Steck et al. (84). Briefly, suspensions of RBCs were
sedimented at 2,300 g for 10 minutes at 4°C, the pellet recovered, and
then resuspended in 5 volumes of cold PBS, pH 8.0. After centrifu-
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gation, packed RBCs were hemolyzed by mixing with 5 mM sodium
phosphate, pH 8.0, and incubating on ice for 1 minute. The resulting
membranes were then harvested by centrifugation at 22,000 g for 10
minutes and the supernatant removed by aspiration.
HT-29 membranes or membranes from the HT-29A–/– line were
prepared as follows. Cells grown in monolayers on a T25 flask were
washed with PBS and the supernatant decanted. After addition of 4
ml fresh PBS, cells were recovered by scraping and the suspension
centrifuged for 5 minutes at 4,200 g. Cell pellets were resuspended
in 1 ml of ice-cold lysis buffer (5 mM PO4, pH 8, 0.5 mg/ml DNase I,
containing Pierce Protease Inhibitor; Thermo Fisher, 88665) and
transferred to a microfuge tube spun for 5 minutes at 3,400 g. Supernatant was removed and replaced with 1 ml fresh lysis buffer. Cells were
then incubated on ice for 30 minutes, flash-frozen in an ethanol-dry
ice bath, and thawed at 37°C. After repeating the freeze-thaw cycles
twice, the extract was passed through a 26-gauge needle 4 to 5 times to
sheer DNA and spun at 25,000 g for 10 minutes at 4°C. The resulting
translucent membrane pellets were then resuspended in PBS.
Erythrocyte ghosts or HT-29 membrane preparations were incubated with ANL-labeled bacterial proteins at 4°C overnight, pelleted
by centrifugation, washed in 1 ml of ice-cold PBS, then resuspended
and boiled in click buffer (50 mM HEPES, 0.5% [w/v] SDS, pH 7.5).
ANL-containing proteins were labeled for 1 hour at 37°C in the dark
with 5 μM tetramethylrhodamine-alkyne (TAMRA-alkyne) (Molecular
Probes) in the presence of 25 mM ascorbate, 1.5 mM CuSO4, and 2.5
mM Tris (3-hydroxypropyltriazolylmethyl)amine. Labeled proteins
were separated by SDS-PAGE in the dark and the gel scanned on a
Typhoon FLA 9500 phosphorimager (GE Healthcare Life Sciences)
using excitation at 532 nm and a 575 nm long-pass filter. Positive control TAMRA-labeled rEtpA was produced by reacting EtpA with 120
μM azidobutyric acid NHS ester (Lumiprobe). The unreacted label
was then removed by dialysis, and the azide-labeled EtpA reacted with
TAMRA-alkyne, as before.
Bio-layer interferometry. Bio-layer interferometry was used to
determine affinity of EtpA–blood group binding using Octet Red96
(Pall ForteBio Corp.). Briefly, biotinylated blood group A antigens
conjugated to PAA (either as the disaccharide GalNAcα1-3Galβ-PAAbiotin; GlycoTech, catalog 01-017; or the trisaccharide GalNAcα1-3
[Fucα1,2]Galβ-PAA-biotin, GlycoTech 01-032) or related target sugars
(α-d-Gal-PAA-biotin, GlycoTech 01-003; GalNAcα1,3GalNAcβ-PAAbiotin, GlycoTech 01-026; αGalNAc-PAA-biotin, GlycoTech 08-010)
were immobilized onto the SA biosensors (18-5019; Pall ForteBio
Corp.). These were then incubated with 2-fold serial dilutions (2000–
500 nM) of purified rEtpA or control BSA (2000 nM) prepared in 1×
PBS as analyte. Affinity constant (kD) values were calculated using
Octet software version 8.1.
Growth and differentiation of human enteroids from different blood
groups. Enteroid experiments were conducted at either John Hopkins
University School of Medicine or at Washington University School of
Medicine, and detailed experimental protocols for both institutions
are included in the Supplemental Methods. In brief, biopsy samples
were obtained from adult patients undergoing routine endoscopy at
each institution. Small intestinal epithelial (enteroid) cell lines were
then generated from dissociated crypts as previously described (85–
87), stored, and then accessed from the Washington University Digestive Diseases Research Core Center Biospecimens Core or the respective aligned program at John Hopkins University School of Medicine.
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3307

RESEARCH ARTICLE

Purified cell lines of each of the described ABO types were thawed
and resuspended in Matrigel (BD Biosciences) and then propagated
at 37°C, 5% CO2 with advanced DEM/F12 media (Invitrogen) supplemented with Wnt3a, R-spondin 1, and Noggin (WRN). Protocols for
cellular differentiation and growth of polarized epithelial monolayers
were performed as described in detail in the Supplemental Methods.
Blood typing by PCR and immunofluorescence microscopy was performed as previously described.
α1-3-N-acetylgalactosaminyltransferase–deficient cell line. Cells
lacking α1-3-N-acetylgalactosaminyltransferase (GI 55773627; GenBank D82843.2) were constructed from HT-29 cells (ATCC HTB38) by CRISPR/Cas9 genome editing in the Genome Engineering
and iPSC Center at Washington University (http://geic.wustl.edu) as
previously reported (45). Both parental HT-29 cells and the resulting
HT-29A–/– line were propagated in McCoy’s-5A medium (Gibco, Life
Technologies) supplemented with 10% FBS.
ETEC adhesion and toxin delivery assays. To examine delivery
of the LT toxin, cultures of HT-29 or HT-29A–/– were differentiated
by growing cultures at confluence for 1 week prior to use in 96-well
plates. Where indicated, phosphodiesterase (PDE) inhibitors vardenafil HCL·3H20 (MilliporeSigma, Y0001647), cilostazol (MilliporeSigma, PHR1503), and rolipram (MilliporeSigma, R6520) were added
to cell cultures 1 hour prior to infections at a final concentration of
6.125 μM (88). ETEC (H10407) or the etpA mutant (jf1668) was grown
overnight in 1 ml of LB media. The following morning, bacteria were
diluted 1:100 for 90 minutes to mid-log growth phase. HT-29 and HT29A–/– were infected with bacteria at an MOI of approximately 100.
MOI was determined by plating serial dilutions of bacterial suspensions and counting HT-29 cells on a hemocytometer after trypsinization of adherent cells. Infection of HT-29 cells by H10407 or the etpA
mutant proceeded for 2 hours at 37°C and 5% CO2 in media containing PDE inhibitors. After 2 hours, the cells were washed once in prewarmed media and the infection continued for an additional hour in
media with PDE inhibitors. Cellular cAMP (Arbor Assays) levels were
used to assess the efficiency of LT delivery.
Adhesion assays were performed as previously described using
mid-log phase bacterial cultures. After 30 minutes, the monolayers
were washed 3 times with prewarmed media, then treated with 0.1%
Triton X-100 in PBS for 5 minutes. Ten-fold dilutions of the Triton
X-100 lysates were plated on Luria agar, and bacterial adherence was
calculated as the percentage of organisms recovered per colony-forming unit of inoculum. Adherence assays for enteroids were performed
in the same fashion, but washed at different time points, as indicated
in the figure legends.
Confocal laser scanning microscopy. HT-29 cells were seeded
onto glass coverslips pretreated with poly-l-lysine in 24-well tissue
culture plates. Enteroids grown on Transwell filters were processed
by removing the filter from the well and then treated as below. Cells
were blocked with 1% BSA in PBS and incubated with biotinylated
EtpA (50 μg/ml final concentration) for 2 hours at 37°C or overnight
at 4°C. After washing with PBS 3 times, EtpA was detected using
Qdot 605 SA conjugate (Life Technologies). A blood group antigen
was detected using mouse monoclonal antibody (IgM; Santa Cruz
Biotechnology Inc., sc-69951) against human blood group A, followed by Alexa Fluor 647–conjugated goat anti-mouse IgM heavy
chain (Molecular Probes, A21238). CellMask deep red plasma membrane stain (Thermo Fisher Scientific, C10046) (1:2,000) and DAPI
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(1:6,000) were used to stain cellular membranes and nuclei, respectively. ETEC H10407 (serotype O78:H11) was visualized with polyclonal rabbit antibodies against O78 obtained from the Penn State
University E. coli Reference Center, followed by detection with goat
anti-rabbit IgG (H&L) cross-absorbed Alexa Fluor (488 or 594) secondary antibody conjugates (Invitrogen, A11070, A11072).
Confocal microscopy images were captured using a Zeiss LSM 510
Meta Confocal Laser Scanning Microscope. Image files were saved in
LSM format and processed using Fiji (89), Image J v 2.0.0 (NIH), and
Volocity 3D analysis software (version 6.3, PerkinElmer).
Blood group typing. Coded, deidentified samples forwarded to
Washington University were used in a blinded fashion to type for the
major ABO blood group antigens. Plasma or serum was used in reverse
immunotyping for antibodies directed at the ABO antigens, which was
performed using standard methods. Briefly 2 μl RBCs (Immucor) from
each blood group were incubated with 4 μl of patient sera or plasma at
RT for 5 minutes in a 96-well plate, then examined microscopically for
agglutination. For available saliva, DNA was extracted from 50 μl of
sample (QIAGEN 69504), and genotyping by PCR was performed as
previously described (90). Salivary genotyping results were confirmed
by dot immunoblotting. Briefly, 0.5 μl saliva diluted 1:4 in PBS was
dotted onto nitrocellulose membranes that were then incubated in a
solution of H2O2 (3%) for 5 minutes. Membranes were then incubated
with 1:20 dilutions of anti-A, anti-B, or anti-H antibodies (MilliporeSigma) for 30 minutes, washed 3 times in PBS with 0.05% Tween, and
probed with goat anti-mouse IgM HRP-conjugate (1:5,000 dilution;
Santa Cruz Biotechnology Inc., sc-2064) and developed using the ECL
Western Blotting Substrate (Thermo Fisher).
ABO determinations were then matched to diarrheal outcomes in
which the severity of illness was dichotomized into none (no or mild
disease) and MSD using established criteria (71).
Statistics. We used log-rank (Mantel-Cox) testing to compare
time-to-treatment outcomes, with P < 0.05 considered significant.
Meta-analysis (pooled fixed effects) was used to compare the relative
risk of moderated to severe diarrheal illness. Pearson χ2 testing was
used to compare diarrheal illness and severity by blood group. MannWhitney U testing was used to compare nonparametric data. More
than 2 groups of data were analyzed using Kruskal-Wallis testing for
multiple comparisons of nonparametric data.
Study approval. Institutional Review Board approval was obtained
at each participating study site (Washington University, the Naval
Medical Research Center, and Johns Hopkins University) prior to
sample interrogation and analysis. Written, informed consent was
received from all participants prior to inclusion in the studies.
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